Download PDF
Aktuelle Neurologie 2016; 43(05): 324-325
DOI: 10.1055/s-0042-108500
Kompetenznetz Multiple Sklerose
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelles aus der Forschung

I. Kleiter
1   Klinik für Neurologie, St. Josef-Hospital, Ruhr-Universität Bochum
,
M. S. Weber
2   Institut für Neuropathologie, Georg-August-Universität, Göttingen
3   Klinik für Neurologie, Georg-August-Universität, Göttingen
› Author Affiliations
Further Information

Publication History

Publication Date:
14 June 2016 (online)

Also available at
    Permissions and Reprints

Behandlung mit Rituximab nach Absetzen von Natalizumab

Aufgrund des PML-Risikos können JCV-Antikörper positive Patienten nur eine begrenzte Zeit mit Natalizumab behandelt werden. Nach wie vor stellt die Umstellung auf eine alternative Therapie eine klinische Herausforderung dar, da es bei diesen Patienten mit hochaktiver MS häufig zu einer Reaktivierung der Erkrankungsaktivität kommt. Bisherige Ansätze mit überbrückender Steroidstoßtherapie, Interferon-beta, Glatiramerazetat oder Fingolimod hatten nur eine begrenzte Wirksamkeit [1].

 

  • Literatur

  • 1 Havla J, Kleiter I, Kumpfel T. Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?. Ther Clin Risk Manag 2013; 9: 361-369
    PubMedGoogle Scholar
  • 2 Alping P, Frisell T, Novakova L et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016; DOI: 10.1002/ana.24651.
    PubMedGoogle Scholar
  • 3 Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688
    CrossrefPubMedGoogle Scholar
  • 4 Roche’s ocrelizumab significantly reduced both relapses and disability progression versus interferon beta-1a (Rebif®) in two Phase III studies in multiple sclerosis. 2015. http://www.roche.com/media/store/releases/med-cor-2015-06-30.html (Accessed 23.04.2016)
    Google Scholar
  • 5 Berger T, Rubner P, Schautzer F et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-145
    CrossrefPubMedGoogle Scholar
  • 6 Gaertner S, de Graaf KL, Greve B et al. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 2004; 63: 2381-2383
    CrossrefPubMedGoogle Scholar
  • 7 Probstel AK, Rudolf G, Dornmair K et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 2015; 12: 46
    CrossrefPubMedGoogle Scholar
  • 8 Mader S, Gredler V, Schanda K et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8: 184
    CrossrefPubMedGoogle Scholar
  • 9 Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383-392
    CrossrefPubMedGoogle Scholar
  • 10 Lucchinetti CF, Guo Y, Popescu BF et al. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 2014; 24: 83-97
    CrossrefPubMedGoogle Scholar
  • 11 Kitley J, Waters P, Woodhall M et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276-283
    CrossrefPubMedGoogle Scholar
  • 12 Sato DK, Callegaro D, Lana-Peixoto MA et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474-481
    CrossrefPubMedGoogle Scholar
  • 13 Hoftberger R, Sepulveda M, Armangue T et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015; 21: 866-874
    CrossrefPubMedGoogle Scholar
  • 14 Lucchinetti CF, Bruck W, Rodriguez M et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-274
    CrossrefPubMedGoogle Scholar
  • 15 Spadaro M, Gerdes LA, Mayer MC et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2015; 2: 295-301
    CrossrefPubMedGoogle Scholar
  • 16 Jarius S, Metz I, König FB et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case. Mult Scler 2016; pii 1352458515622986
    PubMedGoogle Scholar
  • 17 Jarius S, Franciotta D, Paul F et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010; 7: 52
    CrossrefPubMedGoogle Scholar
  • 18 Louveau A, Smirnov I, Keyes TJ et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523: 337-341
    CrossrefPubMedGoogle Scholar
  • 19 Fabriek BO, Zwemmer JN, Teunissen CE et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol 2005; 161: 190-194
    CrossrefPubMedGoogle Scholar
  • 20 Kinzel S, Lehmann-Horn K, Torke S et al. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol 2016; (Epub ahead of print)
    PubMedGoogle Scholar